Combining targeted and immunotherapy: BRAF inhibitor dabrafenib (D) ± the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM)
[摘要]
[发布日期] 2015-01-15 [发布机构]
[效力级别] [学科分类]
[关键词] Metastatic Melanoma;Ipilimumab;Vemurafenib;BRAF Inhibitor;Maculopapular Rash [时效性]
